EGFR and non-small cell lung carcinoma: Mechanistically, miR-483-3p directly targeted integrin β3, consequently inhibiting the downstream FAK/Erk signaling pathway, highlighting miR-483-3p is a prospective target for combination treatment to overcome acquired EGFR TKI resistance in EGFR-mutant NSCLC [226,227].